Skip to Content


In the US, Ponatinib (ponatinib systemic) is a member of the following drug classes: BCR-ABL tyrosine kinase inhibitors, multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia.

US matches:



CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Antineoplastic agent: Tyrosine kinase inhibitor

Chemical Name

3-[2-(imidazo[1,2-b]pyridazin-3-yl)etynyl]-4-metyl-N-{4-[(4-metylpiperazin-1-yl)metyl]-3-(trifluorometyl)phenyl}benzamide (WHO)

Foreign Names

  • Ponatinibum (Latin)
  • Ponatinib (German)
  • Ponatinib (French)
  • Ponatinib (Spanish)

Generic Names

  • Ponatinib (OS: USAN)
  • AP 24534 (IS)
  • UNII-4340891KFS (IS)
  • Ponatinib Hydrochloride (OS: USAN)
  • AP 24534 hydrochloride (IS)
  • UNII-96R6PU3D8J (IS)

Brand Names

  • Iclusig
    ARIAD, Denmark; Ariad Pharma, Slovenia; Haupt Pharma Amareg, Slovakia
  • Iclusing
    Ariad, Spain
  • Iclusig
    Ariad, Austria; Ariad, Ireland; Ariad, Norway; Ariad Pharma, Finland; Ariad Pharma, United Kingdom; Ariad Pharmaceuticals, France

← International Drug Name Search


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.